A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

Jorge Cortes, Hagop Kantarjian, Maher Albitar, Deborah Thomas, Stefan Faderl, Charles Koller, Guillermo Garcia-Manero, Francis Giles, Michael Andreeff, Susan O'Brien, Michael Keating, Elihu Estey

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Fingerprint Dive into the research topics of 'A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences